Thursday, September 24, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 5, 2026

Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering

View original at finance.yahoo.com
Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering Dataset grows to more than 312,000 whole genomes with longitudinal clinical data GSK is one of the first to lead a further expansion of 50,000 whole genomes paired with proteomic data SAN DIEGO, March 5, 20…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Human genetics is the most powerful compass we have for finding the right targets and delivering the best innovative medicines

    80% confidence
  • The AGD dataset is among the largest collections of whole genome sequences available, and it is the world's largest pairing of whole genome sequences with the depth of clinical data that comes from a leading academic medical center

    80% confidence
  • Vanderbilt has an exceptional biobank and population-scale genetics program — one of the most impressive in the world

    80% confidence
  • There is proven value in the integration of proteomics and comprehensive datasets, evidenced by the boon of large-scale studies showing promise in pinpointing drug targets linked to human disease

    80% confidence
  • Integrating high-quality clinical and genomic data with advanced AI will help pharma translate discoveries into meaningful advances for patients

    80% confidence
  • AGD has already enabled disease-impacting discoveries in autoimmune disease and obesity, with many more such studies underway, and continued expansion accelerates this progress

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Go Mainstream, But Trustworthy Data Access Lags Adoption
A wave of enterprise AI agent activity — fresh funding (Latitude's $35M Series A), a run of CB Insights CEO interviews spotlighting fintech- and healthcare-focused agent startups (Covecta, Penguin AI, Maisa AI), and major platform partnerships (Microsoft-Mistral, Manulife-Microsoft AI governance, Siemens-NVIDIA agentic EDA, Box's agent security controls) — signals agentic AI moving from pilot to production across financial and enterprise workflows. Yet Google Cloud's own research shows adoption is outrunning data readiness (companies average AI access to only 45% of their data, with 'data laggards' capped near 30%), while insider selling at incumbent C3.ai hints at mixed investor conviction even as the broader ecosystem accelerates.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,305 source documents archived
Query this data → isubstrate.com